Patents by Inventor Patrick Chames

Patrick Chames has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20190202932
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Methods for selecting binders by phage display and masked selection
    Patent number: 10316315
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 11, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Anti-EGFR conformational single domain antibodies and uses thereof
    Patent number: 10287360
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 14, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université d' Aix-Marseille, Centre National de la Recherche Scientifique (CNRS), CISBIO Bioassays, Institut Jean Paoli & Irene Calmettes
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Anti-mGluR2 conformational single domain antibodies and uses thereof
    Patent number: 10174115
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUD
    Inventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
  • Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
    Patent number: 10174117
    Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Daniel Baty, Patrick Chames, Brigitte Kerfelec, Marc Turini
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 10167345
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: January 1, 2019
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Methods for selecting binders by phage display and masked selection
    Patent number: 9605257
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 28, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Single-domain antibodies that bind to HIV-1 Nef with high affinity
    Patent number: 9512203
    Abstract: The invention relates to antibody fragments with simple heavy chain or sdAbs, characterized in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: December 6, 2016
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Martine Jeanne Pierrette Chartier, Patrick Chames, Serge Salomon Benichou, Stephane Eric Ciogullari, Jerome Christophe Marie Abel Bouchet
  • METHODS FOR SELECTING BINDERS BY PHAGE DISPLAY AND MASKED SELECTION
    Publication number: 20150105266
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 16, 2015
    Inventors: Daniel Baty, Patrick Chames
  • METHODS FOR PREPARING SINGLE DOMAIN ANTIBODY MICROARRAYS
    Publication number: 20140235492
    Abstract: The present invention relates to a method for preparing sd Ab microarray comprising the step consisting of: —i) providing a host cell capable of expressing a biotinylation enzyme —ii) transforming said host cell with a nucleic acid encoding for a fusion protein wherein a single domain antibody is fused at its carboxy terminal end to a biotinylation peptide —iii) culturing said host cell in presence of biotin in such a way that said fusion protein and biotinylation enzyme are expressed, resulting in biotinylation of said fusion protein —iv) lysing said host cell as cultured at step iii) —v) spotting the lysate obtained at step iv) on a solid sup port coated with an agent selected from the group consisting of avidin, streptavidin and/or any art known derivative of these agents A further object of the invention relates to a sd Ab microarray obtainable by the method of the invention.
    Type: Application
    Filed: September 20, 2011
    Publication date: August 21, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicate (INSERM), UNIVERSITE D'AIX MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Klervi Even-Desrumeaux
  • CUSTOM-MADE MEGANUCLEASE AND USE THEREOF
    Publication number: 20140121115
    Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 1, 2014
    Applicant: Cellectis
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Phillipe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, Davie Sourdive
  • Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
    Patent number: 8697395
    Abstract: Use of meganucleases for cleaving DNA in a non-human or an isolated human cell and, in some instances, inducing homologous recombination in said cells and to its application for genome engineering and gene therapy.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: April 15, 2014
    Assignee: Cellectis S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frederic Paques
  • ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS
    Publication number: 20140037631
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Application
    Filed: December 29, 2011
    Publication date: February 6, 2014
    Applicant: UNIVERSITE D'AIX-MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
    Patent number: 8624000
    Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer comprises mutations in the amino acid sequence of SEQ ID NO: 34, wherein said mutations include, (i) at least one and up to five amino acid substitutions from residue Q44 to residue R70, said substitutions selected from the group consisting of substitutions at positions Q44, T46, Y66, R68 and R7; and (ii) at least one and up to six amino acid substitutions from residue Q26 to residue Q38 said substitutions selected from the group consisting of substitutions at positions Q26, K28, N30, S32, Y33 and Q38, and wherein said monomer when in dimeric form binds and cleaves a DNA target sequence. Said dimeric forms include homodimeric, heterodimeric and single-chain I-CreI meganuclease variants.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: January 7, 2014
    Assignee: Cellectis S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frederic Paques
  • ANTIBODY FRAGMENTS INHIBITING HIV NEF PROTEIN
    Publication number: 20130330342
    Abstract: The invention relates to antibody fragments with simple heavy chain or sdAbs, characterised in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.
    Type: Application
    Filed: November 18, 2008
    Publication date: December 12, 2013
    Inventors: Daniel Baty, Martine Jeanne Pierrette Chartier, Patrick Chames, Serge Salomo Benichou, Stéphane Eric Basmaciogullari, Jérôme Christophe Marie Abel Bouchet
  • Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
    Patent number: 8530214
    Abstract: The present invention relates to a polynucleotide encoding a monomer of an I-CreI variant said monomer comprising mutations in the amino acid sequence of SEQ ID NO: 34, wherein said mutations include: (i) at least one and up to eleven amino acid substitutions from residue S22 to Q44 said substitutions selected from the group consisting of substitutions at positions I24, Q26, K28, N30, S32, Y33, Q38, S40 and T42; and (ii) at least one and up to six amino acid substitutions from residue Y66 to I77 said substitutions selected from the group consisting of substitutions at positions Y66, R68, R70, V73 and I77; and wherein said monomer when in dimeric form binds and cleaves DNA.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: September 10, 2013
    Assignee: Cellectis S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Philippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frederic Paques
  • USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF
    Publication number: 20120331574
    Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.
    Type: Application
    Filed: May 31, 2012
    Publication date: December 27, 2012
    Applicant: CELLECTIS S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques
  • USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF
    Publication number: 20120317664
    Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.
    Type: Application
    Filed: May 31, 2012
    Publication date: December 13, 2012
    Applicant: CELLECTIS S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques
  • USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF
    Publication number: 20120304321
    Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.
    Type: Application
    Filed: May 31, 2012
    Publication date: November 29, 2012
    Applicant: CELLECTIS S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques